Why BioAge Labs, Inc.’s (BIOA) Stock Is Down 5.88%
As of Thursday, November 12, BioAge Labs, Inc.’s BIOA share price has dipped by 5.88%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Rosalio Madrigal
Jenna Brashear
Rosalio Madrigal
Jenna Brashear
| Share Statistics | BIOA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $255.1 | $447.9 | 31% |
|
| Shares Out (Mil) | 45.9 | 46.7 | 45% |
|
| Institutional Ownership | 97.0% | 80.9% | 72% |
|
| Float (Mil) | 39.3 | 46.8 | 41% |
|
| Beta | 1.19 | 0.74 | 70% |
|
| Avg Daily Volume (000s) | 618 | 342 | 60% |
|
| Price Change (52-week) |
(30.7%) | 54.7% | 29% |
|
| Growth | BIOA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | na | (1.6%) | na |
|
| EPS (5yr) | na | 15.0% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 8 | |
| Current EPS | ($0.731) | ($2.569) | ($2.619) | |
| Month Ago EPS | ($0.688) | ($2.430) | ($2.512) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | ($0.629) | ($2.374) | ($2.360) | |
| Year/Year Chg | 0.1% | 14.5% | 17.3% | |
| Financials | BIOA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $9 | $303 | 8% |
|
| Net Income (TTM) (Mil) | ($108) | ($10) | 10% |
|
| EPS (TTM) | ($2.545) | ($0.600) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($103) | ($7) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($163) | $1 | 12% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $6 | 20% |
|
| Enterprise Value (Q1) (Mil) | ($104) | $408 | 0% |
|
| Valuation | BIOA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.74 | 2.19 | 17% |
|
| P/E | na | 22.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | BIOA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.5% | na |
|
| Net Margin | na | 3.9% | na |
|
| ROA | (32.0%) | (22.7%) | 16% |
|
| ROE | (34.6%) | (25.0%) | 19% |
|
| Liabilities to Assets | 5.8% | 31.8% | 3% |
|
| F-Score | 3 | 3 | 18% |
|
BioAge Labs, Inc. did not pass any screens on 11/13/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors